NASDAQ:CRMD 12 November 2025

CorMedix Inc. reported Q3 2025 net revenue of $104.3 million and net income of $108.6 million, citing strong DefenCath demand and Melinta portfolio sales. The company raised full-year pro forma revenue guidance to $390–$410 million and expects $115–$135 million in Q4 net revenue. Integration of Melinta is ahead of schedule, with $30 million in synergies targeted by year-end. CorMedix is rebranding as “CorMedix Therapeutics.”